14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PRPO vs ACHV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. PRPO trades at $19.96 (15.4x Forward P/E, -5.3% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRPO vs ACHV. Trailing 12-month operating profitability (PRPO -5.3% vs ACHV 0.0%) and valuation multiples (PRPO 15.4x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PRPO vs ACHV Key Questions & Quantitative Answers
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. PRPO trades at $19.96 (15.4x Forward P/E, -5.3% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
PRPO leads the Growth & Scale pillar: PRPO posts +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRPO generates $28M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, PRPO deploys 49.9% of Rev ($14M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.
PRPO screens cheaper on headline valuation multiples. PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-0.2% EBITDA margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRPO (-8.0% ROE) versus ACHV (-845.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.21β · 96% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.